glp-1 agonists and anesthesia Updated guidance for patients using GLP-1/GIP receptor Glucagon-Like Peptide-1 Receptor Agonists in
Description
For external use only
Adipogen Life Sciences
The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease
Their potential for disease modification and symptom relief, particularly in specific phenotypes, supports their further exploration as part of a personalized treatment approach.
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.
